Merck makes pioneering technologies Gavi, Geri and Gems available to fertility clinics

Merck obtains CE mark certification for consumables of Gavi and Geri as well as for the embryo culture media suite Gems.

“Being able to bring Gavi, Geri and Gems to market so quickly shows how Merck is examining every angle of how fertility treatment outcomes can be improved — from recognizing new technologies to increasing access for patients. Through our work with clinics, we know that fertility laboratories aim to increase the success rate in ART through improved control during embryo development,” said Rehan Verjee, Chief Marketing and Strategy Officer at Merck’s biopharma business. “With these needs of physicians and embryologists in mind, we have aligned our key priorities and are happy to see Gavi, Geri and Gems in full clinical use. These innovative technologies are just the start of our commitment to further expand our portfolio of practical solutions to support women and couples in achieving their dream of having a baby."

All three fertility technologies products were developed to help clinics improve and facilitate treatment decisions using standardized, automated protocols and objective information. In particular, the software module Geri Connect + Assess represents another step towards a suite of software solutions that Merck will soon provide with the goal to further drive innovation in the IVF lab.

Gavi, Geri and Gems are commercialized as part of the partnership between Merck and Genea Biomedx Propriety Limited, Sydney, Australia. Through Merck’s customer and market expertise, the Genea Group’s premium fertility clinics and the world-leading research facility ARTinnovations, the three technologies benefit from both a deep understanding of the patient experience and scientific excellence. “We call the convergence of our expertise in fertility treatment, world leading research and innovation and vigorous in-house testing, our virtuous circle. This unique combination has led us to focus on fertility technologies as the real, game-changing solutions to the challenging issues fertility clinics and people with infertility face,” said Genea CEO Dr Tomas Stojanov.